Dogwood Therapeutics, Inc.

NASDAQ: DWTX · Healthcare · Biotechnology

PublicHQ Alpharetta, GA · FultonCIK 0001818844Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 53DQ —GM —SS 37

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, market scale · ↓ Piotroski F, filing timeliness

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$34.3M

Employees

as of 2026-08-24

Market cap

$83.7M

as of 2026-08-24

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$34.3M-$34.3M2025

Operating income-$28.0M-$28.0M2025

Total assets$90.2M$90.2M2025

Liabilities$15.3M$15.3M2025

Equity$74.9M$74.9M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Dogwood Therapeutics, Inc.’s financial profile?

Dogwood Therapeutics, Inc. earned -$34.3M in FY2025 net income.

Peers · Healthcare

Aldeyra The——Oncolytics Biotech Inc.——Adicet Bio, Inc.——Telomir Pharmaceuticals, Inc. Common Stock——RetinalGenix Technologies Inc.——Cingulate Inc.——

Neighbors

Fulton →

The Coca-Cola Company$47.9B82B+The Home Depot, Inc.$164.7B82B+The Southern Company$28.9B72B United Parcel Service, Inc.$88.7B71B Intercontinental Exchange, Inc.$12.6B76B+Norfolk Southern Corporation$12.2B81B+

Key facts

CEOGregory Duncan

SectorHealthcare

IndustryBiotechnology

HeadquartersAlpharetta, GA

ExchangeNASDAQ: DWTX

Employees8

IPO date2020-12-17

Latest filings

10-Q2026-08-14 8-K2026-08-13 8-K2026-06-17 10-Q2026-05-15 8-K2026-05-14 DEF 14A2026-04-27 8-K2026-03-26 8-K2026-03-18

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.